scout

Harry P. Erba, MD, PhD, Duke Cancer Institute

Articles by Harry P. Erba, MD, PhD, Duke Cancer Institute

Final Thoughts on New Developments and Emerging Agents 

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.  

Treatment Approaches for TP53-Mutated AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Evolving Treatment Approaches Pre- and Post-Transplant

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.

5-Year Follow-up Data on CPX-351 for AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.

The Role of Allogeneic Stem Cell Transplant in AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.

Approaches to Managing Toxicity of Venetoclax

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.

Venetoclax Combination Therapy for IDH-mutated AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.

Combination Approaches Targeting FLT3 and IDH Mutations

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.

Toxicities Associated With IDH Inhibitors

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.

The Role of IDH Inhibitors for Treatment of AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).

Combining and Sequencing FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark J. Levis, MD, PhD, Johns Hopkins University,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.

The Role of FLT3 Inhibitors for Treatment of AML

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.

Molecular Testing Turnaround Time and Treatment Delay

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

Molecular Testing for Acute Myeloid Leukemia

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.

Latest Updated Articles